Lamivudine/Nevirapine/Zidovudine

拉米夫定/奈韦拉平/齐多夫定

Report date: 2022/12/07 17:15:54

Base Information

Drug NameLamivudine/Nevirapine/Zidovudine
Drug Alias Namelamivudine, zidovudine and nevirapine奈韦拉平齐多拉米双夫定 (II)Lamivudine/Zidovudine/Nevirapine奈韦拉平齐多拉米双夫定吉唯久
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2005/01/24
Country/TerritoryUnited StatesMainland China
CombinationsYes NevirapineLamivudineZidovudine
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Desano Pharmaceuticals Co LtdMicro Labs Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Desano Bio-Pharmaceutical Co Ltd
Inactive CompaniesPharmacare LtdMicro Labs LtdNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR05
Related LinksN/A